Hsu R, Brunet L, Fusco J, Vannappagari V, Clark A, Lackey P, Pierone G, Fusco G. Fostemsavir use in the OPERA cohort: immunologic and virologic response. 19th European AIDS Conference (EACS). Warsaw, Poland, October 18-21, 2023.
Research Category: Abstracts and Posters
Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA® Cohort
Sension M, Hsu RK, Fusco JS, Brunet L, Cochran Q, Sridhar G, Vannappagari V, van Wyk J, Wohlfeiler MB, Fusco GP. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA® Cohort. IDWeek. Boston, MA, USA; October 11-15, 2023
Virologic effectiveness of ibalizumab clinical trial experience compared to real-world clinical care without ibalizumab in the OPERA® Cohort.
Brunet L, Jonsson Funk ML, Cash RB, Fusco JS, Walder L, Laws A, Wohlfeiler M, Sension M, Fusco GP. Virologic effectiveness of ibalizumab clinical trial experience compared to real-world clinical care without ibalizumab in the OPERA® Cohort. ACTHIV. Phoenix, AZ, USA, May 4-6, 2023
Demographic and Clinical Characteristics of People in OPERA® with HIV and Heavy Treatment Experience.
Hsu RK, Palmieri Weber R, Fusco JS, Dunbar MS, Gruber J, Marongiu A, Lackey PC, Pierone GJ, Fusco GP. Demographic and Clinical Characteristics of People in OPERA® with HIV and Heavy Treatment Experience. Phoenix, AZ, USA, May 4-6, 2023
Patterns of Doravirine Use in a US Cohort
Sension M, Brunet L, Hsu RK, Mounzer K, Fusco JS, Whiteside YO, Arduino JM, Kolobova I, Fusco GP. Patterns of Doravirine Use in a US Cohort. HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022
Real world use of dolutegravir/lamivudine in treatment naïve people living with HIV during the COVID pandemic
Pierone G, Fusco J, Brunet L, Vannappagari V, Sarkar S, Henegar C, van Wyk J, Zolopa A, Fusco G. Real world use of dolutegravir/lamivudine in treatment naïve people living with HIV during the COVID pandemic. HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022
HIV-Associated Wasting in the Era of Weight Gain
Wohlfeiler M, Palmieri Weber R, Brunet L, Siddiqui J, Harbour M, Phillips A, Hayward B, Fusco J, Hsu R, Fusco G. HIV-Associated Wasting in the Era of Weight Gain. HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022
Comparison of HIV-Associated Wasting Definitions in the OPERA Cohort
Wohlfeiler M, Pamieri Weber R, Brunet L, Siddiqui J, Harbour M, Phillips A, Hayward B, Fusco J, Hsu R, Fusco G. Comparison of HIV-Associated Wasting Definitions in the OPERA Cohort. In HIV Glasgow 2022. Glasgow, United Kingdom; October 23-26, 2022
Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV
Hsu RK, Brunet L, Fusco JS, et al. Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA. [Rapid Fire Poster Session]
Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
Pierone G, Fusco JS, Brunet L, et al. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens. Presented at: IDWeek, October 19-23, 2022; Washington, DC, USA. [Rapid Fire Poster Session]